“In giving, we are connected. Gifts speak for us when the weight of emotion and the vulnerability of truth are too much.” Brown Paper Bags | Journal of Clinical Oncology ascopubs.org/doi/10.1200/...

“Who decides who decides?” Partnered w/ @shrutipatelmd.bsky.social on this editorial from Dr. Campbell & @laurabukavinamd.bsky.social work in which we explore how altmetrics & digital clout are shaped by systemic bias #MedSky #WomenInMedicine ascopubs.org/doi/10.1200/...

⛱️☀️📖 You have heard of “light summer beach reads” — and now @JCO_ASCO brings you “stirring, emotionally powerful, reflective narrative summer writing” (practically the same, right??) But really, what a wonderful opportunity for young writers. ✍🏻📝👨‍💻 @oncoalert.bsky.social

ASCENT04 changes practice w/ improved mPFS 11.2 vs. 7.8 mos; 12 mon PFS 48 vs 33 mos w/ impressive tail suggesting potential for group with durable sustained response; adverse events were not additive. Bonus points for cr up oss over design. #ASCO25 @oncoalert.bsky.social

VERITAC-2 shows vepdegestrant improves PFS after CDK4/6i among pts with HR+ mutESR1 MBc, from 2.1 months to 5.0 months. @erikahamilton9.bsky.social @oncoalert.bsky.social #ASCO25

Reflex cDNA-methylation multi-cancer early detection (MCED) test achieved meaningful per-cancer intrinsic accuracy & per-tissue of origin PPV across mult cancer types evaluated in at-risk indiv w/obesity. #ASCO25 @oncoalert.bsky.social

The chemo-free combo of Ribo+Let+trastuzumab led to mOFS 30.4 months, good ORR, and minimal cardiac toxicity in this ph2 1L Korean study. #ASCO25 @oncoalert.bsky.social

Dr. @hoperugo.bsky.social presents data from 5️⃣ 🇺🇸centers on re-challenge after G1 ILD with T-DXd (n=44), and a small # (n=19) G2 ILD rechallenged. 27% of G1 rechallenged had a second event; 16% of the G2 patients had a second event #ASCO25 @oncoalert.bsky.social

AI-assisted training changed HER-2 low, ultra low, null classification in this analysis by Marina DeBrot et al #ASCO25

Kicking off breast sessions #ASCO25 with the data that Black patients with breast cancer continue to have worse overall survival in the modern-HER2 era. Adjusted HR 1.28 @oncoalert.bsky.social

The #ASCO25 #OncoAlertTOP10 Abstracts in #BreastCancer These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago🇺🇸 @elisaagostinetto.bsky.social‬ @erikahamilton9.bsky.social‬ @drsgraff.bsky.social‬ @elisabettabonzano.bsky.social‬

Join me & Maryam Lustberg at #ASCO25 at #OncForum2025 to discuss ADCs, sequencing, HER2 low/ultra-low, biomarkers, and “right-sizing” early stage disease Saturday June 1 at 7:15- 7:45 PM Duneyrr Fermenta & Brewery 2337 S. Michigan Ave. Register now! app.smartsheet.com/b/form/7e557...

Honored and humbled to be awarded the 2025 E. Grey Diamond Take Wing Award, my school’s highest alumni honor. Thank you, Dean Norbash, my amazing family, members of the awards committee— I am proud to embody the spirit of UMKC SOM in all that I do.

In <1 minute, use @ascocancer.bsky.social link to #ProtectMedicaid. Maybe you think it isn’t about you—but sometimes patients w/cancer lose their job, insurance is tied to employment, then suddenly—Medicaid is about them. Urge members of congress to safeguard Medicaid ➡️brnw.ch/21wSxkd

Congress is considering cuts to Medicaid during its budget reconciliation process. 70 million ppl receive health coverage under Medicaid, including those w/ cancer. We must #ProtectMedicaid! #ASCOAdvocacy Urge members of congress to safeguard Medicaid➡️ brnw.ch/21wSxGD

Oncologists— The @ascocancer.bsky.social #ASCO24 #IDEA awardees are conducting a study to understand and identify barriers, opportunities, and strategies to improve evidence-based cancer care globally. Take a quick survey here: forms.office.com/pages/respon... Cc. @oncoalert.bsky.social

Sacituzumab + Pembro in ASCENT04 improves Progression Free Survival in Patients With Previously Untreated PD-L1 Metastatic Triple-Negative Breast Cancer #bcsm www.gilead.com/news/news-de... @oncoalert.bsky.social

I just had to explain the expression “burning the candle at both ends” to my 9yo. But, yep. #currentsituation

In a multivariable analysis, omitting ET was associated w/⬆️ risk of death HR 1.23; For ER 1%-5% HR 1.16; For ER 6%-10% HR 1.42 Endocrine Therapy Omission in ER–Low (1%-10%) Early-Stage Breast Cancer | @oncoalert.bsky.social ascopubs.org/doi/10.1200/...

Check out this cool profile on all things @dramycomander.bsky.social and Lifestyle Oncology!! @oncologytimes.bsky.social journals.lww.com/oncology-tim...

REAL ID will be *really real* by #ASCO25 —make sure your ID is airport ready. ✈️ @ascocancer.bsky.social @oncbrothers.bsky.social @oncoalert.bsky.social @narjustflorezmd.bsky.social @drchoueiri.bsky.social @erikahamilton9.bsky.social @drdonsdizon.bsky.social @drteplinsky.bsky.social

The act will disenfranchise vets/active/overseas military from voting as well (who often have less access to reams of documents) LDF Denounces House Passage of SAVE Act, Urges Senate to Reject Bill that Will Disenfranchise Millions of Americans - naacpldf.org/press-release/…#HellNoN#VotesForVetsts

Married women who have their husbands last name may need to show 3+ legal documents to verify voter eligibility LDF Denounces House Passage of SAVE Act, Urges Senate to Reject Bill that Will Disenfranchise Millions of Americans - #HellNo #VotesForWomen www.naacpldf.org/press-releas...

This ⬇️

Justice Sotomayor with a bone-chilling dissent today: “The implication of the govt’s position is noncitizens AND US citizens could be taken off streets, forced onto planes, confined to foreign prisons with no opportunity for redress…This Nation's laws is designed to prevent, not en-able, their rise.

@swog.org leaders at @ascocancer.bsky.social #ASCOAdvocacySummit 2025 in DC: Drs. Paul Hesketh, Charles Blanke, Anne Chiang, Raymond Osarogiagbon, Rafeh Naqash. Goals: - Robust federal funding for #CancerResearch, NCI, & NIH - #FixPriorAuth - #DrugShortages solutions

An honor to meet w/Rep.Magaziner staff, Raisa Majid with Drs. Mega & Strenger to discuss key #ASCOAdvocacySummit asks including consistent funding for the NIH, NCI, and ARPA-H; the Improving Seniors' Timely Access to Care Act; partnering on a Solution to End Drug Shortages. @ascocancer.bsky.social

Want to join us in our efforts? Visit asco.org/actnetwork to contact your Members of Congress about the issues that matter most to you! Advocates are also on the Hill to fix #PriorAuth and protect #CancerResearch funding. #ASCOAdvocacy @ascocancer.bsky.social

I am urging lawmakers to ensure long-term stability for oncology treatments, which will ultimately save and prolong lives. With transparency and strong manufacturing, this is preventable. #ASCOAdvocacySummit #drugshortages @ascocancer.bsky.social

We ask Congress & the Administration to intervene to secure the pharmaceutical pipeline & address #drugshortages I have written guidance position⬇️ sat w/clinic pts deciding what to do when we run out of their cancer drug #ASCOAdvocacySummit @ascocancer.bsky.social 🔗 www.asco.org/practice-pat...

Cancer #drugshortages impact both peds& adult populations, causing treatment disruptions & delays, potentially leading to irreversible cancer progression. I am an AssocProfessor & leading cancer researcher—I know my patients, along w/all pts,deserve better #ASCOAdvocacySummit @ascocancer.bsky.social

I am joining over 150 oncologists this week at the #ASCOAdvocacySummit in Washington, D.C. to urge Congress to help address existing #drugshortages and prevent future shortages of lifesaving and life-prolonging cancer drugs. @ascocancer.bsky.social

Had delightful meeting w/Sen. Whitehouse staffer Joe Page w/Drs Mega & Strenger to discuss key #ASCOAdvocacySummit key asks incld consistent funding for the NIH, NCI & ARPA-H; the Improving Seniors' Timely Access to Care Act; partnering on a Solution to End Drug Shortages @ascocancer.bsky.social

ASCO CEO Cliff Hudis joined #RhodeIsland’s #ASCOAdvocacySummit delegates Drs.Mega, Strenger & I meeting w/Senator Reed Our key asks incld consistent funding for NIH, NCI & ARPA-H; the Improving Seniors' Timely Access to CareAct; partnering on a Solution to End DrugShortages @ascocancer.bsky.social

An honor to meet w/ #RepGabeAmo this AM w/Drs. Mega & Strenger to discuss key #ASCOAdvocacySummit asks including consistent funding for the NIH, NCI, and ARPA-H; the Improving Seniors' Timely Access to Care Act; partnering on a Comprehensive Solution to End Drug Shortages. @ascocancer.bsky.social

#RhodeIsland’s own Anthony Mega engaging with the #ASCOAdvocacySummit team around ways oncology clinicians can advocate for prior authorization reform thru Improving Seniors Timely Access to Care Act. #PriorAuth @ascocancer.bsky.social @weldeiry.bsky.social

Hot tips from #ASCOAdvocacySummit #ASCOAdvocacy: A Media Interview (or high profile meeting) is the WRONG TIME for an original thought. Stay on message! Come prepared. Preach! 🙌🏻 🗣️ @ascocancer.bsky.social @lymphomadoc.bsky.social @ishwaria.bsky.social

Can we get more of this? “The Japanese American National Museum will ‘scrub nothing,’ Fujioka said, and instead will highlight the importance of DEI. “Our community is based on diversity, equity is guaranteed to us in the Constitution, and inclusion is what we believe in,” Fujioka said.

Thanks, @ASCO for naming me an Advocacy Champion for my continued commitment to advocating for issues affecting the #oncology community. You can be an Advocacy Champion too by getting involved today: asco.org/actnetwork #ASCOAdvocacySummit

Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis academic.oup.com/oncolo/artic... #SuppOnc #DatoDXd @hoperugo.bsky.social

Have a laugh this morning. I dare you

Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancer www.thebreastonline.com/article/S096...

Identifying surrogate endpoints as valid, reliable primary endpoints is key to advancing cancer care. Partnered on this real-world data analysis demonstrating very strong, positive correlation between iDFS and OS @acsjournalcancer.bsky.social acsjournals.onlinelibrary.wiley.com/doi/full/10....

"Fortunately for our students, Cornell is not a business. We are a university. And universities, despite rapidly escalating political, legal and financial risks, cannot afford to cede the space of public discourse and the free exchange of ideas." www.nytimes.com/2025/03/31/o...

Booker, after speaking for more than 24 hours and breaking Thurmond's record, is still standing and still speaking--using his time to warn his colleagues and his country about the dangers of defunding universities and defunding scientific research.

Corey Booker just raised the bar, concluding with a call for “good trouble.” Now his fellow Dems need to clear it—and raise it higher.

Congratulations @pgrivasmdphd.bsky.social and so many more!! #FASCO

What’s the role of PET in breast cancer? 18F-Labeled Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Staging and Restaging Patients With Breast Cancer | Journal of Clinical Oncology ascopubs.org/doi/full/10....

Women under 40 are experiencing increased rates of breast cancer—Ocean State Stories @pellcenter.bsky.social

Now our breast medical oncology job is posted as well— Our team is GROWING!! 🥳🎆 Come be a part of the fun! Bring the whole crew! #jobalert #oncsky careercenter.asco.org/job/7623746/...